Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Invuity Com USD0.001 (IVTY)
7.07 ? -0.43 (-5.73%)
Volume: 18,991 @ 4:50:31 PM ET
Bid Ask Day's Range
7.01 7.08 6.72 - 7.54
IVTY Detailed Quote Wiki
DAILY/
DAILY/ [-chart]ih.advfn.com/p.php?pid=staticchart&s=IVTY&p=0&t=17&showctype=1&width=336&height=190&vol=1&afterhours=130[/chart]
[-chart]chart.finance.yahoo.com/t?s=IVTY&lang=en-US®ion=US&width=300&height=180[/chart]
[-chart]stockcharts.com/c-sc/sc?s=IVTY&p=D&b=2&g=0&i=p72104498736&r=1395542761133[/chart]
Invuity Com USD0.001 (IVTY)
13.25 ? 0.1101 (0.84%)
Volume: 24,435 @ 4:25:39 PM ET
Bid Ask Day's Range
9.56 17.19 13.06 - 13.5
IVTY Detailed Quote Wiki
$IVTY recent news/filings
bullish
## source: finance.yahoo.com
Fri, 14 Aug 2015 14:21:11 GMT ~ The Joint Commission Recognizes Invuity's® Proprietary Photonics Technology For Improved Patient Safety
[at noodls] - SAN FRANCISCO, July 21, 2015 /PRNewswire/ -- Invuity, Inc. (Nasdaq: IVTY), a leading surgical photonics company, today reported that The Joint Commission has recognized its proprietary photonics technology ...
read full: http://www.noodls.com/view/B321DA7471123D719CD1C51C29A84821F556C5B3
*********************************************************
Fri, 14 Aug 2015 14:21:11 GMT ~ Invuity Names James H. Mackaness Chief Financial Officer
[at noodls] - SAN FRANCISCO, Aug. 10, 2015 /PRNewswire/ -- Invuity, Inc. (NASDAQ:IVTY), a medical technology company, today announced the appointment of medical device financial and operations executive James H. Mackaness ...
read full: http://www.noodls.com/view/6CCD3DCA7E07B3357F7813C26C7FD882692907F7
*********************************************************
Fri, 14 Aug 2015 14:21:11 GMT ~ Invuity Reports 2015 Second Quarter, Six-Month Financial Results
[at noodls] - Second Quarter Revenue Increased 69 Percent Over Prior Year Period SAN FRANCISCO, Aug. 11, 2015 (GLOBE NEWSWIRE) -- Invuity, Inc. (NASDAQ:IVTY), a medical technology company, today reported financial results ...
read full: http://www.noodls.com/view/BFFAF3C9DA2A0B128698D29F3E8D3485C79A939E
*********************************************************
Fri, 14 Aug 2015 14:21:11 GMT ~ Invuity Announces 2015 Second Quarter, Six-Month Results Release and Conference Call Date
[at noodls] - SAN FRANCISCO, July 28, 2015 (GLOBE NEWSWIRE) -- Invuity, Inc. (NASDAQ:IVTY), a leading surgical photonics company, today announced that it will release its 2015 second quarter and six-month financial ...
read full: http://www.noodls.com/view/5F4DDE4372FFE1EF4E3B680CD353689EB2A4BF90
*********************************************************
Thu, 13 Aug 2015 18:59:04 GMT ~ Edited Transcript of IVTY earnings conference call or presentation 11-Aug-15 9:00pm GMT
read full: http://finance.yahoo.com/news/edited-transcript-ivty-earnings-conference-185904830.html
*********************************************************
$IVTY charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$IVTY company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/IVTY/company-info
Ticker: $IVTY
OTC Market Place: Not Available
CIK code: not found
Company name: Invuity, Inc.
Incorporated In:
$IVTY share structure
## source: otcmarkets.com
Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$IVTY extra dd links
Company name: Invuity, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/IVTY/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/IVTY/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=IVTY+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=IVTY+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=IVTY+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/IVTY/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/IVTY/news - http://finance.yahoo.com/q/h?s=IVTY+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/IVTY/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/IVTY/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/IVTY/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/IVTY/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/IVTY/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/IVTY/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/IVTY/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/IVTY/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=IVTY+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/IVTY
DTCC (dtcc.com): http://search2.dtcc.com/?q=Invuity%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Invuity%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Invuity%2C+Inc.&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/IVTY/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/IVTY
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/IVTY/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/IVTY/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/IVTY/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/IVTY/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/IVTY/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/IVTY/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/IVTY/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=IVTY&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=IVTY
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/IVTY/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=IVTY+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=IVTY+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=IVTY
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=IVTY
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=IVTY+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/IVTY/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=IVTY+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/IVTY.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=IVTY
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/IVTY/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/IVTY/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/IVTY/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/IVTY/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/IVTY
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/IVTY
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/IVTY:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=IVTY
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=IVTY
$IVTY DD Notes ~ http://www.ddnotesmaker.com/IVTY
Invuity Com USD0.001 (IVTY)
14.79 ? 0.04 (0.27%)
Volume: 53,712 @ 4:00:00 PM ET
Bid Ask Day's Range
14.58 15.5 14.65 - 14.88
IVTY Detailed Quote Wiki
$IVTY We are a commercial-stage medical technology company pioneering the use of advanced photonics to provide surgeons with improved direct visualization of surgical cavities during minimally invasive and minimal access surgical procedures. We integrate our Intelligent Photonics technology platform into our single-use and reusable advanced surgical devices to address some of the critical intracavity illumination and visualization challenges facing surgeons today. We utilize our proprietary Intelligent Photonics technology to develop optical waveguides that direct and shape thermally cool, brilliant light into broad, uniform and volumetric illumination of the surgical target. We believe that improving a surgeon’s ability to see critical anatomical structures can lead to better clinical and aesthetic outcomes, improved patient safety and reduced surgical time and healthcare costs. We sold our devices to approximately 400 hospitals in the first quarter of 2015, as compared to approximately 200 hospitals in the same quarter of 2014. Based on the number of single-use units we have shipped as of March 31, 2015, we estimate that our devices have been used in over 92,000 surgical procedures. We are also using our Intelligent Photonics technology to develop new devices and modalities to broaden the application and adoption of open minimally invasive and minimal access procedures and enable new advanced surgical techniques.
Photonics is the science and technological applications of light. We have applied advanced principles of photonics to develop our Intelligent Photonics technology platform, which enables the transmission, management and manipulation of light in surgical procedures. Our initial application of this technology is integrated into our family of proprietary optical waveguides. Our waveguides are sophisticated devices that rely on the principles of optics to shape and direct light. They are coupled to a modified fiber optic cable and are designed to work with the standard xenon or LED light sources typically found and utilized in the operating room. Our optical waveguides are incorporated into surgical devices, including our customized line of illuminated surgical retractors, handheld illuminated aspiration devices and drop-in intracavity illuminators. Our handheld illuminated aspiration devices and drop-in intracavity illuminators are single-use products. Our retractors are reusable, but utilize a single-use optical waveguide, which we sell separately because a new waveguide must be used for each procedure.
The fundamental attributes of our optical waveguides include a solid core optical-grade polymer, total internal reflection of light waves, light mixing and extraction by a complex geometry of refractive microstructures or microlenses. The solid core optical-grade polymer waveguide is coupled to a fiber optic cable in order to facilitate the efficient transfer of light. This unique coupling results in our waveguides capturing maximum light with minimal heat build-up. Our waveguides use critical angles and the properties of total internal reflection to retain and transmit maximum light as it travels through the device. In addition, each waveguide utilizes various novel optical methods to mix light during the total internal reflection transmission process to enable more uniform light extraction across its output surface. The output surface consists of a complex geometry of refractive microstructures or microlenses that extract, direct and shape volumetric illumination into the surgical cavity while virtually eliminating shadows and glare. This complex geometric structure extracts and directs light at numerous different angles to enable illumination of the surgical target, even if blood or debris accumulates on the surface of
THIS ONE ????? RAISED CASH. IVTY
Invuity Com USD0.001 (IVTY)
14.92 ? 0.0 (0.00%)
Volume: 100 @ 8:20:03 AM ET
Bid Ask Day's Range
14.66 15.03 - - -
IVTY Detailed Quote Wiki
$IVTY I am loading $IVTY chart up now.
Go $IVTY
$IVTY 85,936 shares bought at $14.92.
Huge Buy
Go $IVTY
$IVTY I am done with update the IBox for IVTY Mick
Go $IVTY
i wil lookie/\
re;
Hey Mick,
I just finished build the iBox (aka Intro-Page) for $IVTY.
http://investorshub.advfn.com/INVUITY-INC-COM-IVTY-29950/
Do you like it?
Go $IVTY
http://investorshub.advfn.com/$Pistol-Pete$-29568/
PART THREE/ THIS TYPE OF PLAN FOR EMPLOYEES? IN FULL/ Securities Registration: Employee Benefit Plan (s-8)
Date : 06/15/2015 @ 12:23PM
Source : Edgar (US Regulatory)
Stock : Invuity Com USD0.001 (MM) (IVTY)
Quote : 14.92 2.18 (17.11%) @ 4:13PM
http://ih.advfn.com/p.php?pid=nmona&article=67288080&symbol=IVTY
Securities Registration: Employee Benefit Plan (s-8)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
//////////////////////////////////////////////////////////
Item 5. Interests of Named Experts and Counsel.
The validity of the issuance of the shares of the Registrant’s common stock offered hereby has been passed upon by Wilson Sonsini Goodrich & Rosati, P.C. (“WSGR”). An investment fund associated with WSGR beneficially owns 2,016 shares of the Registrant’s common stock.
Item 6. Indemnification of Directors and Officers.
Section 145 of the Delaware General Corporation Law authorizes a corporation’s board of directors to grant, and authorizes a court to award, indemnity to officers, directors, and other corporate agents. The Registrant’s amended and restated certificate of incorporation contains provisions that eliminate the personal liability of its directors and officers for monetary damages for breach of their fiduciary duty as directors and officers.
In addition, as permitted by Section 145 of the Delaware General Corporation Law, the amended and restated certificate of incorporation and amended and restated bylaws of the Registrant provide that:
• The Registrant shall indemnify its directors and officers for serving the Registrant in those capacities or for serving other business enterprises at the Registrant’s request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the Registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person’s conduct was unlawful.
• The Registrant may, in its discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law.
• The Registrant is required to advance expenses, as incurred, to its directors and officers in connection with defending a proceeding, except that such director or officer shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification.
• The Registrant will not be obligated pursuant to the amended and restated bylaws to indemnify a person with respect to proceedings initiated by that person, except with respect to proceedings authorized by the Registrant’s board of directors or brought to enforce a right to indemnification.
• The rights conferred in the amended and restated certificate of incorporation and amended and restated bylaws are not exclusive, and the Registrant is authorized to enter into indemnification agreements with its directors, officers, employees and agents and to obtain insurance to indemnify such persons.
• The Registrant may not retroactively amend the bylaw provisions to reduce its indemnification obligations to directors, officers, employees, and agents.
The Registrant’s policy is to enter into separate indemnification agreements with each of its directors and officers that provide the maximum indemnity allowed to directors and executive officers by Section 145 of the Delaware General Corporation Law and also to provide for certain additional procedural protections.
The Registrant also maintains directors and officers insurance to insure such persons against certain liabilities.
These indemnification provisions and the indemnification agreements entered into between the Registrant and its officers and directors may be sufficiently broad to permit indemnification of the Registrant’s officers and directors for liabilities (including reimbursement of expenses incurred) arising under the Securities Act.
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to the Registrant’s directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.
See also the undertakings set out in response to Item 9 herein.
Item 7. Exemption from Registration Claimed.
Not applicable.
Item 8. Exhibits.
See Exhibit Index immediately following the Signature Page.
Item 9. Undertakings.
A. The undersigned Registrant hereby undertakes:
(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
(i) to include any prospectus required by Section 10(a)(3) of the Securities Act;
(ii) to reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement.
Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement;
and
(iii) to include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement.
Provided, however, that paragraphs (A)(1)(i) and (A)(1)(ii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.
(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
B. The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable,
each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
C. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to the Registrant’s directors, officers and controlling persons pursuant to applicable law, the Registrant’s amended and restated certificate of incorporation, amended and restated bylaws,
investor rights agreement or indemnification agreements, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.
In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person in a successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered hereunder,
the Registrant will, unless in the opinion of the Registrant’s counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by the Registrant is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
2
--------------------------------------------------------------------------------
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Francisco, State of California, on June 15, 2015.
INVUITY, INC.
By: /s/ Philip Sawyer
Philip Sawyer
Chief Executive Officer
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Philip Sawyer and Michael Gandy, jointly and severally, as his attorneys-in-fact, with full power of substitution in each, for him in any and all capacities
to sign any amendments to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto and other documents in connection therewith,
with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact, or his substitutes, may do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed below by the following persons in the capacities and on the date indicated.
Signature
Title
Date
/s/ Philip Sawyer
Philip Sawyer
President, Chief Executive Officer and Director
(Principal Executive Officer)
June 15, 2015
/s/ Michael Gandy
Michael Gandy
Chief Financial Officer (Principal Financial and Accounting Officer) June 15, 2015
/s/ Gregory B. Brown
Gregory B. Brown
Director June 15, 2015
/s/ William W. Burke
William W. Burke
Director June 15, 2015
/s/ Randall A. Lipps
Randall A. Lipps
Director June 15, 2015
/s/ Gregory T. Lucier
Gregory T. Lucier
Director June 15, 2015
/s/ Eric W. Roberts
Eric W. Roberts
Director June 15, 2015
/s/ Reza Zadno
Reza Zadno
Director June 15, 2015
Hey Mick,
I just finished build the iBox (aka Intro-Page) for $IVTY.
http://investorshub.advfn.com/INVUITY-INC-COM-IVTY-29950/
Do you like it?
Go $IVTY
PART TWO/ THIS TYPE OF PLAN FOR EMPLOYEES? IN FULL/ Securities Registration: Employee Benefit Plan (s-8)
Date : 06/15/2015 @ 12:23PM
Source : Edgar (US Regulatory)
Stock : Invuity Com USD0.001 (MM) (IVTY)
Quote : 14.92 2.18 (17.11%) @ 4:13PM
http://ih.advfn.com/p.php?pid=nmona&article=67288080&symbol=IVTY
Securities Registration: Employee Benefit Plan (s-8)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
//////////////////////////////////////////////////////////
Title of Securities
to be Registered
Maximum Amount
to be
Registered(1)
Proposed
Maximum
Offering Price
Per Share
Proposed
Maximum
Aggregate
Offering Price
Amount of
Registration Fee
Common Stock $0.001 par value, reserved for issuance pursuant to 2005 Stock Incentive Plan
1,874,220 shares(2) $5.33(4) $9,989,592.60 $1,160.79
Common Stock $0.001 par value, reserved for issuance pursuant to 2015 Equity Incentive Plan
1,661,574 shares(3) $12.00(5) $19,938,888.00 $2,316.90
TOTAL 3,535,794 shares — $29,928,480.60 $3,477.69
(1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement shall also cover any additional shares of the Registrant’s common stock that become issuable pursuant to (i) the Registrant’s 2015 Equity Incentive Plan (the “2015 Plan”) by reason of any dividend or other distribution (whether in the form of cash, shares of the Registrant’s common stock, other securities, or other property), recapitalization, stock split, reverse stock split,
reorganization,
merger,
consolidation,
split-up,
spin-off,
combination,
repurchase, or
exchange of shares of the Registrant’s common stock or other securities of the Company, or other change in the corporate structure of the Registrant affecting the shares of the Registrant’s common stock, or (ii) the Registrant’s 2005 Stock Incentive Plan (the “2005 Plan”) by reason of any subdivision of the outstanding shares of the Registrant’s common stock, declaration of a dividend payable in shares of the Registrant’s common stock, declaration of an extraordinary dividend payable in a form other than shares of the Registrant’s common stock in an amount that has a material effect on the fair market value of the shares of the Registrant’s common stock, combination or consolidation of the outstanding shares of the Registrant’s common stock into a lesser number of shares of the Registrant’s common stock, recapitalization, spin-off, reclassification, or similar occurrence.
(2) Represents 1,874,220 shares of common stock subject to outstanding awards previously granted under the 2005 Plan as of the date of this Registration Statement.
(3) Represents 1,661,574 shares of common stock reserved for issuance pursuant to awards under the 2015 Plan as of the date of the Registration Statement. The shares of common stock subject to outstanding awards previously granted under the 2005 Plan that expire or terminate without having been exercised on or after June 15, 2015 and the shares issued pursuant to awards granted under the 2005 Plan that are forfeited or repurchased by the Registrant on or after June 15, 2015 will be added to the number of shares available for issuance under the 2015 Plan, subject to the limits in the next sentence. No more than 1,874,220 shares of common stock will be added to the 2015 Plan from the 2005 Plan pursuant to the preceding sentence.
(4) Estimated in accordance with Rule 457(h) solely for the purpose of calculating the registration fee. The price of $5.33 represents the weighted average exercise price for outstanding options.
(5) Estimated in accordance with Rule 457(h) solely for the purpose of calculating the registration fee on the basis of $12.00 per share, which is the initial public offering price per share of common stock set forth on the cover page of the Registrant’s Prospectus dated June 15, 2015 relating to the Registrant’s initial public offering.
--------------------------------------------------------------------------------
PART I
INFORMATION REQUIRED IN THE PROSPECTUS
The information specified in Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement on Form S-8 (the “Registration Statement”) in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”), and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the equity benefit plans covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference.
Invuity, Inc. (the “Registrant”) hereby incorporates by reference into this Registration Statement the following documents and information heretofore filed with the Securities and Exchange Commission (the “Commission”):
(1) The Registrant’s Prospectus dated June 15, 2015, filed with the Commission pursuant to Rule 424(b) under the Securities Act, relating to the Registration Statement on Form S-1, as amended (File No. 333-203505), which contains the Registrant’s audited financial statements for the latest fiscal year for which such statements have been filed; and
(2) The description of the Registrant’s common stock contained in the Registrant’s Registration Statement on Form 8-A (File No. 001-37417) filed June 5, 2015 pursuant to Section 12(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendment or report filed for the purpose of updating such description.
All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
Item 4. Description of Securities.
Not applicable.
PART ONE/ THIS TYPE OF PLAN FOR EMPLOYEES? IN FULL/ Securities Registration: Employee Benefit Plan (s-8)
Date : 06/15/2015 @ 12:23PM
Source : Edgar (US Regulatory)
Stock : Invuity Com USD0.001 (MM) (IVTY)
Quote : 14.92 2.18 (17.11%) @ 4:13PM
http://ih.advfn.com/p.php?pid=nmona&article=67288080&symbol=IVTY
Securities Registration: Employee Benefit Plan (s-8)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
INVUITY, INC.
(Exact name of Registrant as specified in its charter)
Delaware 04-3803169
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification Number)
444 De Haro Street
San Francisco, California 94107
(Address of principal executive offices including zip code)
2005 STOCK INCENTIVE PLAN
2015 EQUITY INCENTIVE PLAN
(Full title of the plans)
Philip Sawyer
Chief Executive Officer
Invuity, Inc.
444 De Haro Street
San Francisco, California 94107
(415) 655-2100
(Name, address, and telephone number, including area code, of agent for service)
Copies to:
Steven E. Bochner, Esq.
Allison B. Spinner, Esq.
Wilson Sonsini Goodrich & Rosati
Professional Corporation
650 Page Mill Road
Palo Alto, CA 94304-1050
(650) 493-9300
Brett Robertson
Vice President of Corporate
Development and General Counsel
Invuity, Inc.
444 DeHaro Street
San Francisco, CA 94107
(415) 655-2100
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act (Check one).
Large accelerated filer ¨ Accelerated filer ¨
Non-accelerated filer x (Do not check if a smaller reporting company) Smaller reporting company ¨
--------------------------------------------------------------------------------
CALCULATION OF REGISTRATION FEE
$IVTY INVUITY ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING
SAN FRANCISCO, June 11, 2015 /PRNewswire/ -- Invuity, Inc. today announced the pricing of its initial public offering of 4,000,000 shares of common stock at a public offering price of $12.00 per share, before underwriting discounts and commissions. All of the common stock is being offered by Invuity. In addition, Invuity has granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of common stock from the company at the public offering price. The shares are expected to begin trading on the NASDAQ Global Market on June 12, 2015 under the ticker symbol "IVTY." The offering is expected to close on June 17, 2015, subject to customary closing conditions.
Piper Jaffray, Leerink Partners and Stifel are acting as joint book-running managers for the offering. William Blair is acting as a co-manager.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on June 11, 2015. This offering is being made only by means of a written prospectus forming part of the effective registration statement. When available, copies of the final prospectus relating to this offering may be obtained by contacting: Piper Jaffray & Co., Attention: Equity Capital Markets, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by telephone at 800-747-3924 or by email at prospectus@pjc.com; or Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by telephone at (800) 808-7525, ext. 6142, or by email at syndicate@leerink.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, or by telephone at (415) 364-2720 or by email to syndprospectus@stifel.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/invuity-announces-pricing-of-initial-public-offering-300098202.html
SOURCE Invuity, Inc.
Media: Ashley Paula, Waggener Edstrom, media@invuity.com; Investors: Matt Clawson, Pure Communications, irdept@invuity.com
http://investors.invuity.com/phoenix.zhtml?c=253978&p=irol-newsArticle&ID=2058764
Price IVTY
$14.80 Day's Change
2.80 (23.31%) Bid
14.7
6Ask
14.80
B/A Size
100x600
Day's High
15.20
Day's Low
12.54
Volume (Heavy Day)
Today's volume of 1,068,726 shares is on pace to be much greater than IVTY's 10-day average volume of 0 shares.
1,068,726
Shares Outstanding 12.6M
Market Cap 185.9M
52-Wk Range
0.00 - 15.20
Low/High
Today's News, June 15, 2015
12:15 pm ET *Shares of Invuity Inc. Open for Trade at $12.75, IPO Priced at $12
Benzinga
12:13 pm ET Invuity (IVTY) Resumed Trading
Dow Jones
11:50 am ET Invuity (IVTY) Resumed Trading
Dow Jones
June 12, 2015
2:13 pm ET IPO Scorecard: Update on Selected Initial Stock Offerings
Dow Jones
June 11, 2015
7:06 pm ET Invuity Announces Pricing of Initial Public Offering
PR Newswire
June 09, 2015
11:32 am ET IPO Outlook: Wingstop's 'Atomic' IPO To Top New Issues This Week
Benzinga
$IVTY
StreetInsider
Invuity (IVTY) IPO Opens at $12.75/Share, Above Offering Price
June 15, 2015 12:17 PM
The IPO for Invuity (NASDAQ: IVTY) opened at $12.75 per share, after the company priced 4 million shares of its common stock at $12 apiece last Friday.
Piper Jaffray, Leerink Partners and Stifel are acting as joint book-running managers for the offering. William Blair is acting as a co-manager.
Invuity is a commercial-stage medical technology company pioneering the use of advanced photonics to provide surgeons with improved direct visualization of surgical cavities during minimally invasive and minimal access surgical procedures. The company integrate its Intelligent Photonics technology platform into their single-use and reusable advanced surgical devices to address some of the critical intracavity illumination and visualization challenges facing surgeons today. They utilize their proprietary Intelligent Photonics technology to develop optical waveguides that direct and shape thermally cool, brilliant light into broad, uniform and volumetric illumination of the surgical target. They believe that improving a surgeon's ability to see critical anatomical structures can lead to better clinical and aesthetic outcomes, improved patient safety and reduced surgical time and healthcare costs. The company has sold their devices to approximately 400 hospitals in the first quarter of 2015, as compared to approximately 200 hospitals in the same quarter of 2014. Based on the number of single-use units they have shipped as of March 31, 2015, they estimate that their devices have been used in over 92,000 surgical procedures. They are also using their Intelligent Photonics technology to develop new devices and modalities to broaden the application and adoption of open minimally invasive and minimal access procedures and enable new advanced surgical techniques.
by TaboolaSponsored LinksYou May Like
How This Razor is Disrupting a $13 Billion Industry
Dollar Shave Club
NEVER drink these 2 "types" of MILK (cause weight gain & accelerate aging)
Fat Burning Kitchen Guide Book
7 Outrageous Credit Cards If You Have Excellent Credit
NextAdvisor
New U.S. Currency Law Now In Effect
Stansberry Research
From The Web
How This Razor is Disrupting a $13 Billion Industry (Dollar Shave Club)
NEVER drink these 2 "types" of MILK (cause weight gain & accelerate aging) (Fat Burning Kitchen Guide Book)
7 Outrageous Credit Cards If You Have Excellent Credit (NextAdvisor)
New U.S. Currency Law Now In Effect (Stansberry Research)
These 5 Exercises Age Your Body Faster (Old School New Body eBook)
TriVascular Technologies (TRIV) IPO Opens Lower
Invuity (IVTY) IPO Prices at $12, In-Line with Lower Expectaions
Egalet (EGLT) IPO Opens Higher, Retraces Gains
DAVIDsTEA (DTEA) Boosts Expected IPO Price Range to $17 - $18/Share
RSP Permian (RSPP) Commences 20M Common IPO; Sees Price of $19 - $21/Share
by TaboolaPromoted Links
Categories
Corporate News
IPOs
Trader Talk
Next Articles
Invuity (IVTY) IPO Prices at $12, In-Line with Lower Expectaions
June 12, 2015 9:03 AM
Invuity Announces Pricing of Initial Public Offering
June 11, 2015 7:06 PM
UPDATE: Invuity, Inc. (IVTY) Trims IPO Price Outlook to $12/Share
June 11, 2015 11:05 AM
excerpt at least five I.P.O. INFO/ IPO Outlook: Wingstop's 'Atomic' IPO To Top New Issues This Week
11:32 am ET June 9, 2015 (Benzinga) Print#TheWingExperts fast casual restaurant chain Wingstop (NASDAQ: WING) prepares for its IPO Friday, June 12.
The company initially planned to raise $75 million by offering 5.8 million shares between $12 and $14 per share amid strong demand from investors for restaurant IPOs.
That range has since been updated to between $16 and $18 per share, according to an amended S-1 filing, Benzinga Pro reports.
Wingstop will list on the NASDAQ under the ticker WING. At the midpoint of the range, the company’s market cap would be $372 million.
Wingstop's closest publicly-traded competitor is Buffalo Wild Wings (NASDAQ: BWLD). The Dallas-based company started in Texas in 1994 and has pioneered the concept of chicken wings as the “center of the plate” for all occasions.
The company focuses on chicken, fries, and sides. Ninety percent of its revenue is from its core demographic of 18-34 year Millennials that have grown to love the fast casual restaurant concept as seen with Chipotle (NYSE: CMG) and Shake Shack (NYSE: SHAK).
Wingstop believes that the company’s simple and efficient franchise model of, “chicken, fries, sides, repeat,” has allowed it to scale to 745 locations across 37 states and 6 countries over the last 20 years.
At the end of Q1 in March 2015, its restaurant base was 97 percent franchised with 726 locations and 19 company-owned restaurants.
The restaurant’s low initial capital investment and strength in the fast casual space has helped franchisees generate strong operating margins, consistent free cash flow and capital efficient growth.
The company’s same store sales have increased 11 years through 2014 and its restaurant count has grown at a CAGR of 15.3 percent.
Financials
Total revenue, including royalties and franchise fees as well as company-owned restaurant sales equaled $19 million for Q1 of 2015 compared with $16.8 million at the end of Q1 in 2014.
Revenue increased due to an increase in the number of franchise stores from 608 to 726 and the domestic same store sales growth of 10.7 percent from primarily an increase in transaction counts.
Revenue over the last three years grew year over from $25.1 million in 2012 to $30.2 million in 2013 and to $38.0 million in 2014. The majority of the company's royalty agreements require franchisees to pay 5.0 percent of gross sales net of discounts.
The good news for franchisees is that upon opening, the restaurant does not experience the typical “honeymoon effect" often cited in the industry.
Wingstop’s S-1, in particular, notes that growth remains consistent with the average store doing $820,000 of revenue its first 52 weeks in business. In 2014, 59 of 82 new restaurant openings were by existing franchisees.
The company is able to improve cost controls by leveraging fixed costs with labor, for example. Labor costs decreased as a percentage of sales from 22.5 percent in 2014 to 20.6 percent in 2015.
Net income decreased to $2.55 million in Q1 of 2015 from $2.98 million over the same time period in 2014.
Net income grew year over from 2012 to 2014 from $3.58 million, $7.53 million, and $8.98 million respectively.
Shifting to the balance sheet, the company has $2.90 million in cash, $114 million in total assets and, $133 million in total debt.
Prior to the offering, the company is 85 percent owned by Atlanta-based private equity firm Roark Capital Management and after the offering will maintain 69.9 percent.
When Roark acquired Wingstop in 2010, it issued a press release in which its managing director Steve Romaniello said “Roark invests in franchises with a proven track record in the marketplace and potential for significant growth.
With 27 consecutive quarters of positive same-store sales, Wingstop is a clear leader in its category.” At the time, the deal was valued between $80 and $90 million or about 7 to 8 times Ebitda.
Wingstop has paid a $48 million dividend to Roark this year as well as a $38.5 million dividend in 2014 and a $19.3 million dividend in 2012.
The fast casual restaurant industry is expected to exceed $54 billion in annual sales by 2018, up 57 percent from $34.5 million currently, according to Technomic.
The company’s domestic restaurant count increased 43.3 percent since the end of 2011 with restaurant openings continuing to increase each year.
With the company’s fast growth and market appeal, it aims to capture market share away from its competition as it plans to expand to 2,500 locations.
Conclusion And Pricing Info
Given Wingstop’s strong year over year growth, simple and efficient franchise model, and timing in the fast casual space, this looks to be a hot IPO issue.
Wingstop expects the next proceeds of this offering to equal $22.9 million to go toward the repayment of $19.6 million in debt and a $3.3 million management fee to terminate its agreement with Roark Capital Management.
Other Offerings
Thursday June 11
Invuity (NASDAQ: IVTY) 4.0 million shares expect to price at a range of $14 to $16 per share through Piper Jaffray, Leerink, and Stifel.
Axovant Sciences (NYSE: AXON) 17.9 million shares expect to price at a range of $13 to $15 per share through Jeffries, Evercore, and RBC Capital Markets.
Friday June 12
Biotie Therapies (NASDAQ: BITI):
3.37 million shares expect to price at $14.82 through RBC Capital Markets, Stifel, and JMP Securities.
Peoples Utah Bancorp (NASDAQ: PUB): 2.5 million shares expect to price at a range of $13 to $14 per share through D.A. Davidson, Sandler O’Neill + Partners, and FIG partners
Principle Solar (NASDAQ: PSWW): 2.5 million shares expect to price at a range of $9 to $11 per share through Northland Securities.
Wingstop: 5.8 million shares expect to price $16 to $18 per share through Morgan Stanley, Jeffries, and Baird.
Yulong Eco-Materials (NASDAQ: YECO): 2.3 million shares expect to price at a range of $6.25 to $7.25 per share through Axiom Capital Management and Northland Securities.
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Securities Registration: Employee Benefit Plan (s-8) "Edgar (US Regulatory)" - 6/15/2015 12:23:42 PM
Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp) "Edgar (US Regulatory)" - 6/15/2015 9:41:12 AM
Post-effective Amendment to Registration Statement (pos Am) "Edgar (US Regulatory)" - 6/12/2015 1:09:31 PM
Notice of Effectiveness (effect) "Edgar (US Regulatory)" - 6/12/2015 6:01:38 AM
Invuity Com USD0.001 (IVTY)
14.92 ? 2.18 (17.11%)
Volume: 1,635,954 @ 4:01:23 PM ET
Bid Ask Day's Range
14.75 14.9 12.54 - 15.2
IVTY Detailed Quote Wiki
Followers
|
2
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
91
|
Created
|
06/15/15
|
Type
|
Free
|
Moderators |
CORPORATE PROFILE |
Invuity is a medical technology company focused on pioneering the use of advanced photonics to provide surgeons with improved direct visualization of surgical cavities during open minimally invasive and minimal access procedures. Invuity's patented Intelligent Photonics technology enables superior illumination and visualization and is designed to overcome the significant limitations of traditional surgical lighting options in the operating room.
Invuity, Inc.
444 De Haro Street
San Francisco, CA 94107
415-655-2100
Philip Sawyer has served as our Chief Executive Officer and a member of our board of directors since March 2010 and as our President since June 2012. In 2008, Mr. Sawyer co-founded Helix Ventures, a healthcare venture capital fund. In 1993, Mr. Sawyer co-founded Fusion Medical Technologies, a surgical sealant company, where he held the positions of President and Chief Executive Officer for nine years, guiding the company through two private financings, an initial public offering and an acquisition by Baxter International. Mr. Sawyer worked in marketing and business development at Stryker Corporation from 1991 to 1993. Mr. Sawyer received a B.A. in political science from Haverford College and an M.B.A. from Harvard Business School. We believe Mr. Sawyer is qualified to serve as a member of our board of directors because of the perspective he brings as our Chief Executive Officer and his management, operational and investment experience in the healthcare industry.
http://www.bloomberg.com/research/stocks/private/person.asp?personId=211072&privcapId=52419231
Eric W. Roberts has served as a member of our board of directors since June 2012. Since January 2012, Mr. Roberts has been a founding Managing Director of Valence Life Sciences. Since June 2006, Mr. Roberts has been a founding Managing Director of Caxton Advantage Venture Partners. From 1986 to 2004, Mr. Roberts served in a variety of roles as an investment banker, including as Managing Director and Partner at Dillon, Read & Co. and Managing Director and Co-Head of the Healthcare Investment Banking Group at Lehman Brothers. Mr. Roberts received a B.S. in economics from the Wharton School of the University of Pennsylvania. We believe Mr. Roberts is qualified to serve as a member of our board of directors because of his experience as an investment banker and venture capitalist in the healthcare industry.
Reza Zadno, Ph.D. has served as a member of our board of directors since January 2013. Since January 2015, Dr. Zadno has served as an Innovation Advisor to Novartis Venture Fund and has served as an Executive in Residence at InterWest Partners, a venture capital firm, where he served as a Venture Partner from January 2012 to December 2014. From January 2011 to January 2012, Dr. Zadno served as a Venture Partner at New Leaf Venture Partners, a venture capital firm. From March 2001 to September 2009, Dr. Zadno was founder, President, and Chief Executive Officer of Visiogen, a medical device company, which was acquired by Abbott-Medical Optics, a medical supply company, in 2009, at which time Dr. Zadno served as its General Manager until January 2011. From August 2000 to March 2001, Dr. Zadno worked as Entrepreneur in Residence at Three Arch Partners, a healthcare investment firm. Dr. Zadno currently serves on the board of directors of Carbylan Therapeutics, Oraya Therapeutics and Gobiquity. Dr. Zadno received a Ph.D. (Docteur-Ingenieur) in Mechanical Properties of Materials from Ecole des Mines de Paris. We believe Dr. Zadno is qualified to serve on our board because of his medical background, venture capital experience and his leadership and management experience.
Randall A. Lipps has served as a member of our board of directors since June 2013. In September 1992, Mr. Randall founded Omnicell, a publicly traded automated healthcare solutions company, and has served as its Chairman of the Board since that time and as its President and Chief Executive Officer since October 2002. From 1989 to 1992, Mr. Lipps served as the Senior Vice President of ST Holdings, a travel and marketing company. From 1987 to 1989, he served as Assistant Vice President of Sales and Operations for a subsidiary of AMR, the parent company of American Airlines. Mr. Lipps received both a B.S. in economics and a B.B.A. from Southern Methodist University. We believe Mr. Lipps is qualified to serve on our board of directors because of his management and operational experience in the healthcare industry.
Invuity is a medical technology company focused on pioneering the use of advanced photonics to provide surgeons with improved direct visualization of surgical cavities during open minimally invasive and minimal access procedures. Our patented Intelligent Photonics technology enables superior illumination and visualization and is designed to overcome the significant limitations of traditional surgical lighting options in the operating room.
Our patented Intelligent Photonics is integrated into our single-use and reusable advanced surgical devices to address some of the critical intracavity illumination and visualization challenges facing surgeons today. These devices utilize our proprietary optical waveguide technology to direct and shape thermally cool, brilliant light into broad, uniform and volumetric illumination of the surgical target.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |